Market increase or gouging?

October 18, 2011 11:30 AM Eastern Daylight Time 

The Atrial Fibrillation Drug Market Will Increase Nearly Eight-Fold over the Next Decade, Growing from $1.3 Billion in 2010 to over $10 Billion in 2020

Key Market Drivers Include the Launch and Rapid Uptake of New Oral Anticoagulants and Atrial-Selective Antiarrhythmic Drugs, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the atrial fibrillation drug market will increase nearly eight-fold over the next decade, growing from $1.3 billion in 2010 to more than $10 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The launch and rapid uptake of new oral anticoagulants, atrial-selective antiarrhythmic drugs, and the expanding prevalent patient population will be the key drivers of market growth.

“Eliquis is the only emerging anticoagulant to show both increased efficacy and lower rates of major bleeding compared with warfarin and results from its Phase III program have been met with strong enthusiasm from interviewed thought leaders”

The findings from the Pharmacor topic entitled Atrial Fibrillation reveal that stroke prevention in atrial fibrillation is undergoing a transformation and is the most active area of drug development in this indication. A wave of new oral anticoagulants, with clinical profiles superior to that of warfarin (Bristol-Myers Squibb’s Coumadin, Eisai’s Warfarin, generics), will capture 72 percent of the market by 2020. The leading anticoagulants will be Bristol-Myers Squibb/Pfizer’s Eliquis, Daiichi Sankyo’s Lixiana and Boehringer Ingelheim’s Pradaxa.

Eliquis, owing to the strength of its clinical data, is expected to overshadow its rivals, Pradaxa and Bayer/Janssen’s Xarelto, which were further ahead in development.

“Eliquis is the only emerging anticoagulant to show both increased efficacy and lower rates of major bleeding compared with warfarin and results from its Phase III program have been met with strong enthusiasm from interviewed thought leaders,” said Decision Resources Analyst Matthew Killeen, Ph.D. “Given the overwhelming unmet need for safer alternatives to warfarin and Eliquis’s unique value proposition, we expect Eliquis to emerge as the sales-leading anticoagulant for atrial fibrillation with sales of more than $3 billion in 2020.”

The findings also reveal that drug development is not limited to anticoagulants in the atrial fibrillation market. Several promising novel antiarrhythmic drugs that are in early- to mid-stage development have the potential to offer profound safety advantages over current therapies. Cardiome/Merck’s oral vernakalant, one of the most promising new oral antiarrhythmic drugs expected to launch for atrial fibrillation over the next ten years, is forecast to garner blockbuster sales in 2020.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders

via businesswire.com

Posted via email from Jack's posterous